MSLN and neoplasm: A recent phase I clinical trial (NCT01675765) aimed to investigate the safety and the anti-tumor immune response of the administration of cancer vaccine CRS-207 (an attenuated form of Listeria monocytogenes engineered to stimulate an immune response against mesothelin), with or without cyclophosphamide, followed by standard chemotherapy in MPM patients.